First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.
Date
2021-01-15ICR Author
Author
Aeppli, S
Schmaus, M
Eisen, T
Escudier, B
Grünwald, V
Larkin, J
McDermott, D
Oldenburg, J
Porta, C
Rini, BI
Schmidinger, M
Sternberg, CN
Rothermundt, C
Putora, PM
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more recently by the incorporation of immune checkpoint inhibitors (ICI). Today, a spectrum of single agent TKI to TKI/ICI and ICI/ICI combinations can be considered and the choice of the best regimen is complex. MATERIALS AND METHODS: We performed an updated decision-making analysis among 11 international kidney cancer experts. Each expert provided their treatment strategy and relevant decision criteria in the first line treatment of mccRCC. After the collection of all input a list of unified decision criteria was determined and compatible decision trees were created. We used a methodology based on diagnostic nodes, which allows for an automated cross-comparison of decision trees, to determine the most common treatment recommendations as well as deviations. RESULTS: Diverse parameters were considered relevant for treatment selection, various drugs and drug combinations were recommended by the experts. The parameters, chosen by the experts, were performance status, International Metastatic renal cell carcinoma Database Consortium (IMDC) risk group, PD-L1 status, zugzwang and contraindication to immunotherapy. The systemic therapies selected for first line treatment were sunitinib, pazopanib, tivozanib, cabozantinib, ipilimumab/nivolumab or pembrolizumab/axitinib. CONCLUSION: A wide spectrum of treatment recommendations based on multiple decision criteria was demonstrated. Significant inter-expert variations were observed. This demonstrates how data from randomized trials are implemented differently when transferred into daily practice.
Collections
Subject
clear cell renal cell carcinoma
decision-making
immune checkpoint inhibitor
systemic treatment
tyrosine kinase inhibitor
Carcinoma, Renal Cell
Humans
Immunotherapy
Kidney Neoplasms
Sunitinib
Language
eng
Date accepted
2020-12-02
License start date
2021-01-15
Citation
ESMO Open, 2021, 6 (1), pp. 100030 -
Publisher
ELSEVIER